Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Cost of RevenueEBIATGross ProfitShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Exousia Bio (LMMY) Gross Profit (2023 - 2025)

Lamy (LMMY) has disclosed Gross Profit for 3 consecutive years, with -$62108.0 as the latest value for Q4 2025.

  • Quarterly Gross Profit changed N/A to -$62108.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$69359.0 through Nov 2025, down 4160.83% year-over-year, with the annual reading at -$3501.0 for FY2025, 291.0% down from the prior year.
  • Gross Profit hit -$62108.0 in Q4 2025 for Lamy, down from -$7251.0 in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $3875.0 in Q4 2023 to a low of -$62108.0 in Q4 2025.
  • Historically, Gross Profit has averaged -$10629.3 across 3 years, with a median of -$1083.5 in 2024.
  • Biggest YoY gain for Gross Profit was 22.55% in 2025; the steepest drop was 22.55% in 2025.
  • Year by year, Gross Profit stood at $3875.0 in 2023, then dropped by 3.23% to $3750.0 in 2024, then tumbled by 1756.21% to -$62108.0 in 2025.
  • Business Quant data shows Gross Profit for LMMY at -$62108.0 in Q4 2025, -$7251.0 in Q2 2025, and $3750.0 in Q3 2024.